(CMRX/GENR)—Astute call on CMRX's Ebola program. Those kinds of nuances are what make listening to webcasts a required task for serious biotech investors. I got out of GENR about 10 years ago (before the crash) based on a webcast that suggested something was amiss with the Squalamine dosing in wet AMD (#msg-4420204, #msg-4454949).
Inasmuch as GENR was my largest holding at the time (and was the main topic of this message board), my decision to sell based on a subtle hint of trouble surprised a lot of people.
Curiously, Squalamine (now formulated as an eye drop) is still being studied by OHRP.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.